Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Schizophrenia Clinical Trial

Official title:

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02237235
• Other study ID #: STU00098144
• Status: Completed
• Phase: Phase 2
• First received: September 9, 2014
• Last updated: August 31, 2017
• Start date: August 2014
• Est. completion date: August 2017

Study information

• Verified date: August 2017
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with stable levels of positive symptoms. Secondary end points will include changes in positive and negative symptoms. One dose of MMFS-202-302 will be studied and compared with placebo as adjunctive treatment to atypical antipsychotic drug treatment.

Description:

One of the symptoms of schizophrenia is a problem with specific domains of cognition, even when the positive symptoms have been treated. The primary goal of this study is to determine the effectiveness of 9 weeks of supplementation with MMFS-202-302 as augmentation of atypical antipsychotic medication, to improve a critical specific domain of cognitive function, i.e., working memory, in patients with schizophrenia or schizoaffective disorder. To support this primary goal, global function will be assessed with the Clinical Global Impression assessment of change.

The investigators will also examine the effect of MMFS-202-302 on other domains of cognition (e.g. attention, executive function, declarative memory, etc.); negative symptoms of schizophrenia; positive symptoms of schizophrenia; MRI measures of brain structure, resting state functional connectivity, and function during evaluation of emotional/unemotional and rewarding/aversive images and anticipation and receipt of reward and punishment, and working memory; and EEG measurement of network interactivity during learning and memory recollection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: August 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. All patients must be capable of giving written informed consent.

2. Male or female subjects of any race; between 18 to 60 years of age, inclusive.

3. No hospitalization other than for evaluation in the past four months

4. Resides in a stable living situation, according to the investigator's judgment.

5. Diagnosis of schizophrenia or schizoaffective disorder of at least one-year duration, as established by the SCID-I, and verified with medical records and/or confirmation of diagnosis by treating clinician. The illness is in a nonacute phase as determined by the subject's primary treating clinician

6. Current psychotropic drug treatment consists of monotherapy with an atypical antipsychotic drug.

7. No more than a mild level of EPS as determined by the Simpson Angus Scale (SAS) total score: = 6

8. Not taking anticholinergic medication for EPS

9. No evidence of tardive dykinesia

10. Subjects healthy enough to complete a 9-week clinical trial

11. Women of childbearing potential must have a negative pregnancy test at screening and baseline, and agree to use adequate protection (i.e. double barrier method) for birth control.

12. Able to complete cognition assessments in English

13. General intellectual abilities falling broadly within the average estimated IQ > 80, as measured by the Wide Range Achievement Test - 4th Edition (WRAT-IV).

Exclusion Criteria:

1. Failure to perform screening or baseline examinations

2. Hospitalization within 8 weeks before screening, or change of antipsychotic medication or dose within 2 months prior to screening

3. Subjects who have participated in another clinical trial with an experimental medication within the past 2 months.

4. Patient has had cognitive battery similar to those used in this study within the last 12 months

5. Subjects with other DSM-V Axis I or Axis II primary diagnoses

6. Diagnosis of alcohol or substance abuse or dependence within the past 3 months,

7. Significant suicide risk as determined by the Columbia Suicide Severity Rating Scale (C-SSRS)

8. Subjects who plan to begin a new course of cognitive remediation therapy, or have been receiving cognitive remediation therapy for less than one year. .

9. History of myocardial infarction, unstable angina, uncontrolled hypotension or hypertension within 3 months before screening.

10. Clinically significant abnormality on screening ECG

11. Alanine transaminase (ALT) or aspartate transaminase (AST) > 2.5 times the upper limit of normal (ULN)

12. History of stroke, brain tumor, head trauma with loss of consciousness, or other clinically significant neurological condition within 12 months before screening

13. Subjects with other uncontrolled medical conditions, in the opinion of the investigator

14. Polypharmacy with two or more antipsychotic drugs or mood stabilizers

15. Use of benzodiazepines

16. Individuals with kidney dysfunction will not be enrolled, as dysfunctional kidneys may have difficulty clearing the magnesium from the body

17. Individuals who are currently taking magnesium supplements

Related Conditions & MeSH terms

• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia

Intervention

Drug:
• MMFS-202-302
Active ingredient: L-Threonic acid Magnesium salt. 1 g (2 pills) by mouth once daily in the evening for 9 weeks Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt 1 g (2 pills) by mouth once daily in the morning for 9 weeks
• Placebo
Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.

Locations

Country	Name	City	State
United States	Northwestern University Psychiatric Clinical Research Program	Chicago	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
Northwestern University	Brain & Behavior Research Foundation, Neurocentria, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) total score		Baseline to Day 63
Other	Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) speed of processing domain subscale score		Baseline to Day 63
Other	Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) attention/vigilance domain subscale score		Baseline to Day 63
Other	Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) verbal learning domain subscale score		Baseline to Days 42 and 63
Other	Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) visual learning domain subscale score		Baseline to Day 63
Other	Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) reasoning and problem solving domain subscale score		Baseline to Day 63
Other	Change from Baseline in cognition measured by the MATRICS Consensus Cognitive Battery (MCCB) social cognition domain subscale score		Baseline to Day 63
Other	Change from Baseline in cognition measured by the FAS Phonemic Fluency test		Baseline to Day 63
Other	Change from Baseline in cognition measured by the Brown-Peterson's Auditory Consonant Trigrams test		Baseline through Day 63
Other	Change from Baseline in cognitive outcomes among subgroups of subjects with deficits in the respective cognitive domain	Cognitive outcomes will be reanalyzed, restricted to the subgroup of subjects whose baseline score is at or below median for healthy age-matched norms (T-score of 50 or below) for the respective cognitive outcome of interest. Analogous analyses will be carried out using more conservative cutoffs of one half and one standard deviation below median (T-score of 45 and 40 or below).	Baseline to Day 63
Other	Change from Baseline in cognition measured by the Wisconsin Card Sorting Test		Baseline to Day 63
Other	Change from Baseline in working memory composite score		Baseline to Day 63
Other	Change from Baseline in Negative symptoms measured by the Brief Negative Symptom Scale (BNSS)		Baseline to Day 63
Other	Change from Baseline in Negative symptoms measured by the Positive and Negative Syndrome Scale (PANSS) negative symptom subscale		Baseline to Day 63
Other	Change from Baseline in Negative symptoms measured by the Calgary Depression Scale for Schizophrenia (CDSS)		Baseline to Day 63
Other	Change from Baseline in Positive symptoms measured by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale		Baseline to Days 42 and 63
Other	Overall clinical global impression of severity improvement measured by the change from Baseline of Clinical Global Impressions Scale assessment of severity (CGI-S)		Baseline to Day 63
Other	Change from Baseline in brain structure and function	Magnetic Resonance Imaging (MRI) measures of brain structure; resting state functional connectivity; and activation patterns during performance of a working memory paradigm, and of brain reward networks during affective/neutral image appraisal and reward/loss anticipation and outcome (regions of interest: OMPFC, ACC, NAc, VTA).	Baseline to Day 63
Other	Change from Baseline neural activity and connectivity during learning and memory recollection measured by EEG		Baseline to Day 63
Other	Change from Baseline of red blood cell magnesium levels in relation to efficacy outcome measures	Red blood cell magnesium level will be evaluated as a putative surrogate biomarker of target engagement, as a predictor of efficacy.	Baseline to Day 63
Other	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	To evaluate safety and tolerability of MMFS-202-302 in patients with schizophrenia or schizoaffective disorder maintained on a stable dose of an atypical antipsychotic, each grade of adverse event will be evaluated individually, as well as the total number of all grades of adverse events	Baseline through Day 63, or Early Termination
Other	Responder analyses	The number of subjects achieving a cutoff of improving at least one half of a standard deviation (T-score change > 5) on the working memory subscale of the MCCB will be compared between the MMFS-202-302 and Placebo groups. Analogous responder analyses will be carried out for other efficacy outcomes.	Baseline to Day 63
Primary	Matrics Consensus Cognitive Battery (MCCB)	Change from Baseline in MATRICS Consensus Cognitive Battery (MCCB) working memory domain.	Baseline to Day 63
Secondary	Overall clinical global impression of severity improvement measured by the Clinical Global Impressions Scale assessment of change (CGI-C)	To support the primary endpoint of working memory, the CGI-C will demonstrate clinically relevant improvement of global function.	Day 63